Abstract:In this review we have surveyed recent investigations of early cellular events in pulmonary fibrosis both in animal models and in human diseases. Analysis of the interactions of the numerous cell types in the lung following injury is an almost overwhelmingly complex enterprise. In the animal models experimental design has a profound effect on results, making it difficult to compare studies when species, fibrogenic agent, dose, route of exposure, schedule of administration, time course, and analytical methods may not be equivalent. In human diseases we are rarely able to obtain data at precisely the same time point in the course of the disease even among patients in the same study, and possible confounding variables present are legion. Transcending these difficulties for the moment, can we draw any conclusions from our current knowledge of early cellular interactions in pulmonary fibrosis? What is striking is not that there are so many agents that can potentially induce pulmonary fibrosis, but that the lung has such capabilities for recovery. Although the major effector cells may all initially participate in damaging the lung and initiating fibrosis, there is evidence that they may also have the capacity to participate in subsequent repair. Macrophages may initially recruit fibroblasts and stimulate them to proliferate, only to suppress them subsequently. Macrophage production of prostaglandins can lead to suppression of macrophage, neutrophil and lymphocyte responses, thus attenuating tissue injury and the development of fibrosis. Neutrophils may initially release toxic metabolites and enzymes that damage parenchyma. However, there is evidence that they may later play a role in attenuating fibrosis, perhaps through collagenase secretion, or through as yet unknown mechanisms. Lymphocytes may initially participate in a number of damaging ways by secreting chemoattractants for other cells and participating in destructive autoimmune processes. However, there is evidence that subpopulations of T cells may dramatically shift during the course of fibrosis, leading to attenuation of the process. It may thus be useful to consider irreversible pulmonary fibrosis as the end result of a process in which the balance of normal injury/repair mechanisms is disrupted. There is clearly no single "fibrogenic event." Rather, there seem to be a number of places where disruption of balance/repair processes may begin. In diseases of unknown etiology such as sarcoidosis or IPF, loss of control may occur at the genetic level, leading to the destructive alveolitis that is the apparent precursor of fibrosis.(ABSTRACT TRUNCATED AT 400 WORDS)

Regeneration-Associated Transitional State Cells in Pulmonary Fibrosis

Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis

New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis

Cross-species integration of single-cell RNA-seq resolved alveolar-epithelial transitional states in idiopathic pulmonary fibrosis

Regulating the cell shift of endothelial cell-like myofibroblasts in pulmonary fibrosis

Lung regeneration: diverse cell types and the therapeutic potential

Metabolic reprogramming of pulmonary fibrosis

Regulatory Mechanisms of TGF‐β1‐induced Fibrogenesis of Human Alveolar Epithelial Cells

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)

Tissue remodelling in pulmonary fibrosis

New aspects of the epigenetic regulation of EMT related to pulmonary fibrosis

Early cellular events in pulmonary fibrosis

Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis

Progressive Pulmonary Fibrosis is Caused by Elevated Mechanical Tension on Alveolar Stem Cells

Transitional cell states sculpt tissue topology during lung regeneration

Epithelial-Mesenchymal Transition Contributes to Pulmonary Fibrosis via Aberrant Epithelial/Fibroblastic Cross-Talk

Aberrant Transitional Alveolar Epithelial Cells Promote Pathogenic Activation of Lung Fibroblasts in Preclinical Fibrosis Modeling

Stem cell-based therapy for pulmonary fibrosis

Biomechanical Properties and Cellular Responses in Pulmonary Fibrosis

Pulmonary fibrosis: pathogenesis and therapeutic strategies